

26

+

Please use a plus sign (+) inside this box → ☒

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/435,471
Filing Date	November 8, 1999
First Named Inventor	Denise R. Cooper
Group Art Unit	1632
Examiner Name	Anne Marie Baker
Attorney Docket Number	USF-T135

Sheet 1 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Am2	R1	AMARA, F.M. <i>et al.</i> "Defining a Novel <i>cis</i> -Element in the 3'-Untranslated Region of Mammalian Ribonucleotide Reductase Component R2 mRNA" <i>J. Biol. Chem.</i> , August 1996, 271(33):20126-20131.	
	R2	BLOBE, G.C. <i>et al.</i> "Protein Kinase C β II Specifically Binds to and Is Activated by F-actin" <i>J. Biol. Chem.</i> , June 1996, 271(26):15823-15830.	
	R3	CANETE-SOLER, R. <i>et al.</i> "Characterization of Ribonucleoprotein Complexes and Their Binding Sites on the Neurofilament Light Subunit mRNA" <i>J. Biol. Chem.</i> , May 1998, 273(20):12655-12661.	
	R4	CHALFANT, C.E. <i>et al.</i> "Regulation of Alternative Splicing of Protein Kinase C β by Insulin" <i>J. Biol. Chem.</i> , June 1995, 270(22):13326-13332.	
	R5	HARA, K. <i>et al.</i> "1-Phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for RAS activation in CHO cells" <i>Proc. Natl. Acad. Sci., USA</i> , August 1994, 91:7415-7419.	
	R6	MCCLAIN, D.A. <i>et al.</i> "Glucose and glucosamine regulate growth factor gene expression in vascular smooth muscle cells" <i>Proc. Natl. Acad. Sci., USA</i> , September 1992, 89:8150-8154.	
	R7	NAKSHATRI, H. and P. BHAT-NAKSHATRI "Multiple parameters determine the specificity of transcriptional response by nuclear receptors HNF-4, ARP-1, PPAR, RAR and RXR through common response elements" <i>Nucleic Acids Res.</i> , 1998, 26(10):2491-2499.	
	R8	NIINO, Y.S. <i>et al.</i> "Positive and Negative Regulation of the Transcription of the Human Protein Kinase C β Gene" <i>J. Biol. Chem.</i> , March 1992, 267(9):6158-6163.	
	R9	OBEID, L.M. <i>et al.</i> "Cloning and Characterization of the Major Promoter of the Human Protein Kinase C β Gene" <i>J. Biol. Chem.</i> , October 1992, 267(29):20804-20810.	
	R10	PALMER, R.H. <i>et al.</i> "Activation of PRK1 by Phosphatidylinositol 4,5-Bisphosphate and Phosphatidylinositol 3,4,5-Trisphosphate" <i>J. Biol. Chem.</i> , September 1995, 270(38):22412-22416.	
	R11	PROKIPCAK, R.D. <i>et al.</i> "Purification and Properties of a Protein That Binds to the C-terminal Coding Region of Human <i>c-myc</i> mRNA" <i>J. Biol. Chem.</i> , March 1994, 269(12):9261-9269.	
	R12	QUILLIAM, L.A. <i>et al.</i> "Isolation of a NCK-associated Kinase, PRK2, an SH3-binding Protein and Potential Effector of Rho Protein Signaling" <i>J. Biol. Chem.</i> , November 1996, 271(46):28772-28776.	
Am2	R13	RON, D. <i>et al.</i> "Cloning of an intracellular receptor for protein kinase C: A homolog of the β subunit of G proteins" <i>Proc. Natl. Acad. Sci. USA</i> , February 1994, 91:839-843.	

Examiner
Signature

Anne-Marie Falk

Date
Considered

12/13/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Compleat if Known

Application Number	09/435,471
Filing Date	November 8, 1999
First Named Inventor	Denise R. Cooper
Group Art Unit	1632
Examiner Name	Anne Marie Baker
Attorney Docket Number	USF-T135

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Ama	R14	ROSS, J. "mRNA Stability in Mammalian Cells" <i>Microbiology Reviews</i> , September 1995, 59(3):423-450.	
Ama	R15	SAYESKI, P.P. and J.E. KUDLOW "Glucose Metabolism to Glucosamine Is Necessary for Glucose Stimulation of Transforming Growth Factor- α Gene Transcription" <i>J. Biol. Chem.</i> , June 1996, 271(25): 15237-15243.	
Ama	R16	VINCENT, S. and SETTLEMAN, J. "The PRK2 Kinase Is a Potential Effector Target of both Rho and Rac GTPases and Regulates Actin Cytoskeletal Organization" <i>Mol. Cell. Biol.</i> , April 1997, 17(4):2247-2256.	
	R17		
	R18		
	R19		
	R20		
	R21		
	R22	RECEIVED	
	R23	NOV 20 2002	
	R24	TECH CENTER 1600/2900	
	R25		
	R26		

Examiner
Signature

Anne-Marie Jalk

Date
Considered

12/13/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

28

+

RECEIVED


PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 09/435,471
 Filing Date November 8, 1999
 First Named Inventor Denise R. Cooper
 Group Art Unit 1632
 Examiner Name Anne Marie Baker
 Attorney Docket Number USF-T135

TECH CENTER 1500/2900

DEC 2 2002

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Am2	R1	AMANO, M. <i>et al.</i> "Identification of a Putative Target for Rho as the Serine-Threonine Kinase Protein Kinase N" <i>Science</i> , February 1996, 271(5249):648-650.	
	R2	AMARA, F.M. <i>et al.</i> "A <i>cis-trans</i> Interaction at the 3'-Untranslated Region of Ribonucleotide Reductase mRNA Is Regulated by TGF- β_1 , TGF- β_2 , and TGF- β_3 " <i>Biochem. and Biophysical Res. Comm.</i> , 1996, 228:347-351.	
	R3	BENBOW, U. and C.E. BRINCKERHOFF "The AP-1 Site and MMP Gene Regulation: What Is All the Fuss About?" <i>Matrix Biology</i> , 1997, 15:519-526.	
	R4	BERNSTEIN, P.L. <i>et al.</i> "Control of <i>c-myc</i> mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant" <i>Genes Dev.</i> , 1992, 6:642-654.	
	R5	CHUNG, J. <i>et al.</i> "PDGF- and insulin-dependent pp70 ^{src} activation mediated by phosphatidylinositol-3-OH kinase" <i>Nature</i> , July 1994, 370:71-75.	
	R6	HANSEN, W.R. <i>et al.</i> "The 3'-nontranslated region of rat renal glutaminase mRNA contains a pH-responsive stability element" <i>Amer. J. Physiology</i> , July 1996, 271:F126-F131.	
	R7	JIA, Z. "Protein phosphatases: structures and implications" <i>Biochem. Cell Biol.</i> , 1997, 75:17-26.	
	R8	KEMP, B.E. and R.B. PEARSON "Protein kinase recognition sequence motifs" <i>Trends Biochem. Sci.</i> , September 1990, 15(9):342-346.	
	R9	MUKAI, H. and Y. ONO "A Novel Protein Kinase with Leucine Zipper-Like Sequences: Its Catalytic Domain is Highly Homologous to That of Protein Kinase C" <i>Biochem. Biophys. Res. Comm.</i> , March 1994, 199(2):897-904.	
	R10	NEWTON, A.C. "Regulation of protein kinase C" <i>Curr. Opin. Cell Biol.</i> , 1997, 9:161-167.	
	R11	NISHIZUKA, Y. "Studies and Perspectives of Protein Kinase C" <i>Science</i> , July 1986, 233(4761):305-312.	
✓	R12	NISHIZUKA, Y. "Intracellular Signaling by Hydrolysis of Phospholipids and Activation of Protein Kinase C" <i>Science</i> , October 1992, 258(5082):607-614.	
Am2	R13	NISHIZUKA, Y. "Protein kinase C and lipid signaling for sustained cellular responses" <i>FASEB J.</i> , 1995, 9:484-496.	

Examiner Signature	Anne-Marie Falk	Date Considered	12/13/02
--------------------	-----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/435,471
Filing Date	November 8, 1999
First Named Inventor	Denise R. Cooper
Group Art Unit	1632
Examiner Name	Anne Marie Baker
Attorney Docket Number	USF-T135

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Amz	R14	OREKHOV, A.N. et al. "Cellular Composition of Atherosclerotic and Uninvolved Human Aortic Subendothelial Intima" <i>Am J. Pathol.</i> , 1984, 115:17-24.	
	R15	PALMER, R.H. and P.J. PARKER "Expression, purification and characterization of the ubiquitous protein kinase C-related kinase 1" <i>Biochem. J.</i> , 1995, 309:315-320.	
	R16	PATEL, N.A. et al. "Acute hyperglycemia regulates transcription and posttranscriptional stability of PKCβII mRNA in vascular smooth muscle cells" <i>FASEB J.</i> , 1999, 13:103-113.	
	R17	PERROTTI, D. et al. "TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis" <i>The EMBO J.</i> , 1998, 17(15):4442-4455.	
	R18	PREKERIS, R. et al. "Identification and Localization of an Actin-binding Motif That Is Unique to the Epsilon Isoform of Protein Kinase C and Participates in the Regulation of Synaptic Function" <i>J. Cell Biol.</i> , January 1996, 132(1-2):77-90.	
	R19	RIDLEY, A.J. et al. "The Small GTP-Binding Protein rac Regulates Growth Factor-Induced Membrane Ruffling" <i>Cell</i> , August 1992, 70:401-410.	
	R20	ROSS, R. "The Pathogenesis of Atherosclerosis—An Update" <i>N. Eng. J. Med.</i> , February 1986, 314(8):488-500.	
	R21	SANTEN, R.J. et al. "Atherosclerosis in Diabetes Mellitus. Correlations With Serum Lipid Levels, Adiposity, and Serum Insulin Level" <i>Arch. Intern. Med.</i> , December 1972, 130(6):833-843.	
	R22	SCHWARTZ, S.M. et al. "Replication of Smooth Muscle Cells in Vascular Disease" <i>Circ. Res.</i> , April 1986, 58(4):427-444.	
	R23	SHIBA, T. et al. "Characterization of the Activation of Protein Kinase C Isoenzymes in the Retina of Diabetic Rats" <i>Diabetes</i> , 1990, 39(Supplement 1):31A. Abstract No. 123.	
	R24	TAKAI, Y. et al. "Studies on a Cyclic Nucleotide-independent Protein Kinase and Its Proenzyme in Mammalian Tissues" <i>J. Biol. Chem.</i> , November 1977, 252(21):7603-7609.	
Amz	R25	WATANABE, G. "Protein Kinase N (PKN) and PKN-Related Protein Rho as Targets of Small GTPase Rho" <i>Science</i> , February 1996, 271(5249):645-648.	
	R26		

Examiner Signature	Anne-Marie Jalk	Date Considered	12/13/02
--------------------	-----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.